Skip to main content
Erschienen in: Head and Neck Pathology 3/2017

20.03.2017 | PROCEEDINGS OF THE 2017 NORTH AMERICAN SOCIETY OF HEAD AND NECK PATHOLOGY COMPANION MEETING (SAN ANTONIO, TX)

Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry

verfasst von: Aaron M. Udager, Simion I. Chiosea

Erschienen in: Head and Neck Pathology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

More than 15 years ago, seminal studies by Dr. E. Leon Barnes and colleagues transformed our understanding of salivary duct carcinoma (SDC) and, in doing so, paved the way for contemporary diagnostic and therapeutic approaches to this aggressive salivary adenocarcinoma. In particular, attention to the apocrine phenotype of SDC and expression of androgen receptor (AR) by immunohistochemistry has improved the diagnostic accuracy and showed how SDC can be reliably distinguished from its morphologic mimics (i.e., other salivary gland carcinomas with high grade transformation, low grade cribriform cystadenocarcinoma, and squamous cell carcinomas involving parotid). Furthermore, the observation that SDC shares AR expression with prostate cancer and apocrine breast cancer foresaw the discovery of common molecular alterations between SDC and these tumor types and draw attention to androgen deprivation therapy for SDC patients.
Literatur
1.
Zurück zum Zitat Kleinsasser O, Klein HJ, Hubner G. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192(1):100–5.CrossRefPubMed Kleinsasser O, Klein HJ, Hubner G. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192(1):100–5.CrossRefPubMed
2.
Zurück zum Zitat Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24(4):579–86.CrossRefPubMed Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24(4):579–86.CrossRefPubMed
3.
Zurück zum Zitat Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998;11(11):1033–8.PubMed Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998;11(11):1033–8.PubMed
4.
Zurück zum Zitat Williams L, Thompson LD, Seethala RR, Weinreb I, Assaad AM, Tuluc M, et al. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. Am J Surg Pathol. 2015;39(5):705–13. doi:10.1097/PAS.0000000000000413.CrossRefPubMed Williams L, Thompson LD, Seethala RR, Weinreb I, Assaad AM, Tuluc M, et al. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. Am J Surg Pathol. 2015;39(5):705–13. doi:10.​1097/​PAS.​0000000000000413​.CrossRefPubMed
6.
8.
Zurück zum Zitat Nagao T, Gaffey TA, Visscher DW, Kay PA, Minato H, Serizawa H, et al. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Am J Surg Pathol. 2004;28(3):319–26.CrossRefPubMed Nagao T, Gaffey TA, Visscher DW, Kay PA, Minato H, Serizawa H, et al. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Am J Surg Pathol. 2004;28(3):319–26.CrossRefPubMed
9.
Zurück zum Zitat Henley JD, Seo IS, Dayan D, Gnepp DR. Sarcomatoid salivary duct carcinoma of the parotid gland. Hum Pathol. 2000;31(2):208–13.CrossRefPubMed Henley JD, Seo IS, Dayan D, Gnepp DR. Sarcomatoid salivary duct carcinoma of the parotid gland. Hum Pathol. 2000;31(2):208–13.CrossRefPubMed
10.
Zurück zum Zitat Nagao T, Gaffey TA, Serizawa H, Iwaya K, Watanabe A, Yoshida T, et al. Sarcomatoid variant of salivary duct carcinoma: clinicopathologic and immunohistochemical study of eight cases with review of the literature. Am J Surg Pathol. 2004;122(2):222–31. doi:10.1309/5J40-08QR-Y1HW-W5W4. Nagao T, Gaffey TA, Serizawa H, Iwaya K, Watanabe A, Yoshida T, et al. Sarcomatoid variant of salivary duct carcinoma: clinicopathologic and immunohistochemical study of eight cases with review of the literature. Am J Surg Pathol. 2004;122(2):222–31. doi:10.​1309/​5J40-08QR-Y1HW-W5W4.
11.
Zurück zum Zitat Simpson RH, Prasad AR, Lewis JE, Skalova A, David L. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2003;27(8):1070–9.CrossRefPubMed Simpson RH, Prasad AR, Lewis JE, Skalova A, David L. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2003;27(8):1070–9.CrossRefPubMed
14.
15.
Zurück zum Zitat In: Weinreb I, Seethala RR, Chiosea SI, Perez-Ordonez B, Hyrcza M, Zhang L et. al., editors. Molecular analysis of low-grade cribriform cystadenocarcinoma & related in-situ and invasive carcinomas. New York: Nature Publishing Group, 2016. In: Weinreb I, Seethala RR, Chiosea SI, Perez-Ordonez B, Hyrcza M, Zhang L et. al., editors. Molecular analysis of low-grade cribriform cystadenocarcinoma & related in-situ and invasive carcinomas. New York: Nature Publishing Group, 2016.
16.
Zurück zum Zitat Brandwein-Gensler M, Hille J, Wang BY, Urken M, Gordon R, Wang LJ, et al. Low-grade salivary duct carcinoma: description of 16 cases. Am J Surg Pathol. 2004;28(8):1040–4.CrossRefPubMed Brandwein-Gensler M, Hille J, Wang BY, Urken M, Gordon R, Wang LJ, et al. Low-grade salivary duct carcinoma: description of 16 cases. Am J Surg Pathol. 2004;28(8):1040–4.CrossRefPubMed
19.
22.
Zurück zum Zitat Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. doi:10.1172/JCI45014.CrossRefPubMedPubMedCentral Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. doi:10.​1172/​JCI45014.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espie M, et al. Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer. 2013;132(5):1227–31. doi:10.1002/ijc.27767.CrossRefPubMed Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espie M, et al. Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer. 2013;132(5):1227–31. doi:10.​1002/​ijc.​27767.CrossRefPubMed
26.
Zurück zum Zitat Chiosea SI, Thompson LD, Weinreb I, Bauman JE, Mahaffey AM, Miller C, et al. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations. Cancer. 2016;122(20):3136–44. doi:10.1002/cncr.30179.CrossRefPubMed Chiosea SI, Thompson LD, Weinreb I, Bauman JE, Mahaffey AM, Miller C, et al. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations. Cancer. 2016;122(20):3136–44. doi:10.​1002/​cncr.​30179.CrossRefPubMed
28.
Zurück zum Zitat van der Hulst RW, van Krieken JH, van der Kwast TH, Gerritsen JJ, Baatenburg de Jong RJ, Lycklama a Nijeholt AA et al. Partial remission of parotid gland carcinoma after goserelin. Lancet. 1994;344(8925):817.CrossRefPubMed van der Hulst RW, van Krieken JH, van der Kwast TH, Gerritsen JJ, Baatenburg de Jong RJ, Lycklama a Nijeholt AA et al. Partial remission of parotid gland carcinoma after goserelin. Lancet. 1994;344(8925):817.CrossRefPubMed
29.
Zurück zum Zitat van Krieken JH. Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am J Surg Pathol. 1993;17(4):410–4.CrossRefPubMed van Krieken JH. Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am J Surg Pathol. 1993;17(4):410–4.CrossRefPubMed
30.
Zurück zum Zitat Locati LD, Perrone F, Cortelazzi B, Lo Vullo S, Bossi P, Dagrada G et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck. 2014. doi:10.1002/hed.23940. Locati LD, Perrone F, Cortelazzi B, Lo Vullo S, Bossi P, Dagrada G et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck. 2014. doi:10.​1002/​hed.​23940.
Metadaten
Titel
Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry
verfasst von
Aaron M. Udager
Simion I. Chiosea
Publikationsdatum
20.03.2017
Verlag
Springer US
Erschienen in
Head and Neck Pathology / Ausgabe 3/2017
Elektronische ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-017-0798-x

Weitere Artikel der Ausgabe 3/2017

Head and Neck Pathology 3/2017 Zur Ausgabe

PROCEEDINGS OF THE 2017 NORTH AMERICAN SOCIETY OF HEAD AND NECK PATHOLOGY COMPANION MEETING (SAN ANTONIO, TX)

OSPs and ESPs and ISPs, Oh My! An Update on Sinonasal (Schneiderian) Papillomas

Neu im Fachgebiet Pathologie